A Randomized Study of Lenvatinib 18 mg Vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Publication Title
The Journal of clinical endocrinology and metabolism
Document Type
Article
Publication Date
10-19-2021
Keywords
RR-DTC; lenvatinib; starting dose; tyrosine kinase inhibitor; oregon; portland; chiles
Abstract
BACKGROUND: Lenvatinib is a multikinase inhibitor approved to treat radioiodine-refractory differentiated thyroid cancer (RR-DTC) at a starting dose of 24 mg/day. This study explored, in a double-blinded fashion, whether a starting dose of 18 mg/day would provide comparable efficacy with reduced toxicity.
METHODS: Patients with RR-DTC were randomized to lenvatinib 24 mg/day or 18 mg/day. The primary efficacy endpoint was objective response rate as of Week 24 (ORRwk24); odds ratio noninferiority margin: 0.4. The primary safety endpoint was frequency of grade ≥3 treatment-emergent adverse events (TEAEs) as of Week 24. Tumors were assessed using RECIST v1.1. TEAEs were monitored and recorded.
RESULTS: The ORRwk24 was 57.3% (95% confidence interval [CI] 46.1-68.5) in the lenvatinib 24-mg arm and 40.3% (95% CI 29.3-51.2) in the lenvatinib 18-mg arm, with an odds ratio [18/24 mg] of 0.50 (95% CI 0.26-0.96). As of Week 24, the rates of TEAEs grade ≥3 were 61.3% in the lenvatinib 24-mg arm and 57.1% in the lenvatinib 18-mg arm, a difference of -4.2% (95% CI -19.8-11.4).
CONCLUSION: A starting dose of lenvatinib 18 mg/day did not demonstrate noninferiority compared with a starting dose of 24 mg/day as assessed by ORRwk24 in patients with RR-DTC. The results represent a clinically meaningful difference in ORRwk24. The safety profile was comparable, with no clinically relevant difference between arms. These results support the continued use of the approved starting dose of lenvatinib 24 mg/day in patients with RR-DTC and adjusting the dose as necessary.
Clinical Institute
Cancer
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Oncology
